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Abstract 
Review on Germinal center B-cell-like diffuse Large 
B-cell Lymphoma (GCB) DLBCL, with data on 
clinics, and genes. 
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Clinics and pathology 
Disease 
Diffuse large B-cell lymphoma (DLBCL) accounts 
for approximately 30% to 40% of all non-Hodgkin 
lymphoma (NHL) cases. (Sujobert P, et al., 2016) 
Gene expression profiling (GEP) studies have 
identified ≥ 2 distinct molecular subtypes, termed 
germinal center B-cell (GCB) and activated B-cell 
(ABC), which are believed to represent lymphomas 
arising from different stages of lymphoid 
differentiation. (Alizadeh AA, et al., 2000; 
Rosenwald A, et al., 2002) The GCB DLBCL 
represent approximately 50% of DLBCL. (Karmali 
R, et al., 2017). 
GCB DLBCLs are thought to arise from normal 
germinal center B cells and show features that are 
consistent with germinal center B cell derivation. 
(Alizadeh AA, et al., 2000; Rosenwald A, et al., 
2002)  These harbor oncogenetic hits typical such as 
t(14:18) translocation, the mutations of epigenetic 
modifiers ( EZH2, KMT2D) or mutations in the 
genes encoding the S1PR2 receptor or its signal 
transduction protein GNA13. (Sehn L, et al., 2015) 
This subtype has a cure rate of about 70 to 80% with 
currently available immune chemotherapy regimens 
like R-CHOP, R-DHAP, R-ICE or DA-EPOCH-R. 
(Thieblemont C, et al., 2011; Delarue R, et al., 2013; 
Cunningham D, et al., 2013) 
Etiology 
GCB DLBCLs are believed to derived from 
lymphoid cells residing in the germinal center and 
therefore express genes normally detected in 
germinal center B cells, such as CD10, LMO2 and 
the transcriptional repressor Bcl6. (Béguelin W, et 
al., 2013; Sujobert P, et al., 2016; Lenz G et al. 2008) 
Approximately 30% to 40% of GCB DLBCLs have 
a t(14:18) translocation, 30% have REL 
amplifications, 20% have mutations of the histone 
methyltransferase EZH2 and 10% have a deletion of 
the PTEN, all of which are virtually never seen in 
ABC DLBCL. (Pfeifer M, et al., 2013; Morin RD, et 
al., 2011; Pasqualucci L, et al., 2011) 
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Epidemiology 
The median age is 70 years old (occur in children and 
adults). The incidence is between 25-30% of adult 
NHL's (western countries), with slight male 
predominance. 
Pathology 
GC-DLBCL is described as CD-10 positive, Bcl-6 
positive and MUM-1 negative. (Sujobert P, et al., 
2016) 
Treatment 
It is the most curable subtype, with a 5-year overall 
survival (OS) rate of nearly 75%. The GC subtype 
has a cure rate of about 70 to 80% with currently 
available therapies. The infusional regimen of dose-
adjusted etoposide, cyclophosphamide, doxorubicin, 
vincristine, prednisone, and rituximab (DA-
EPOCH-R) or Hyper CVAD-R, have yield 
promising results especially in the GC- DLBCL 
subtype. (Petrich AM, et al., 2014) Similarly, R-
CHOP, R-DHAP and R-ICE could be valuable 
options of treatment. (Delarue R, et al., 2013; 
Cunningham D, et al., 2013). In the new era of 
targeted therapy, it could soon benefit from 
inhibitors of the EZH2, Bcl-2 and Bcl-6 
oncoproteins. 
Genetics 
GC-DLBCL largely express gene products, such as 
Bcl-6, GCSAM (HGAL) and LMO2 that define 
normal germinal center B cells within the germinal 
center light zone. (Alizadeh AA, et al., 2000; 
Rosenwald A, et al., 2002) Malignant GC-DLBCL 
clones continue to undergo somatic hypermutation 
of their variable immunoglobulin heavy chain gene 
and have often switched IgH classes that are 
mediated by AID, an enzyme that is 
characteristically expressed at high levels in 
germinal center B cells. (Lossos IS, et al., 2000) The 
GC-DLBCL subtype is characterized by low level of 
NF-kB activation and its survival is not dependent 
on NF-kB. (Davis RE, et al., 2001; Dal Porto JM, et 
al., 2004)  
 
Translocation of BCL2and/or MYC genes, are 
commonly observed in GC-DLBCL. These 
translocation lead to constitutive activation of c-
MYC and the anti-apoptotic Bcl-2 protein and to a 
malignant transformation by preventing terminal 
differentiation or blocking apoptosis. (Shaffer 3rd 
AL, et al., 2012) 20% have gain of function 
mutations of the histone methyltransferase EZH2, 
which is a master regulator of the GC-DLBCL 
phenotype and cooperates, partly with Bcl-2 and 
BCL6 to mediate lymphomagenesis. Is also 
characterized by downregulation of the phosphatase 
and tensin homologue (PTEN) and concomitant 
upregulation of phosphatidylinositol-3-kinase 
(PI3K) signaling pathway. (Sehn L, et al., 2015) 
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